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Introduction
Hereditary spastic paraplegias (HSP) are a group of clinically and genetically diverse 
diseases characterised by progressive and severe lower limb spasticity per se or in 
combination with other neurological features. SPG3A mutation is the most frequent cause 
of autosomal-dominant hereditary spastic paraplegia (ADHSP) with an onset before the age 
of 10 years.1 This gene, located at chromosome 14q, was identified in 2001. It is responsible 
for the encoding of atlastin, a 558-amino acid protein, which is a member of the dynamin 
family of large guanosine triphosphatases.2,3 It is unclear how the lack of atlastin causes 
the symptoms of HSP. Recent research suggests that atlastin is found predominantly in 
the brain, particularly in the pyramidal neurones in the cerebral cortex and hippocampus, 
and is an integral membrane protein involved in Golgi membrane dynamics or vesicle 
trafficking in brain-specific axonal growth.3,4 Over 30 different mutations, mainly missense 
mutations, have been reported in the SPG3A gene,4 and family studies have failed to reveal 
any genotype-phenotype correlation in cases of ADHSP.5 We report a family where three 
members have a clinical diagnosis of idiopathic spastic paraplegia caused by a missense 
mutation in the SPG3A gene.
Case report
The proband (III-2) is a 6-year-old boy who was referred to a paediatric clinic at the 
age of 3 years for developmental delay and a tiptoe gait. He is the second child of non-
consanguineous Chinese parents. His antenatal and perinatal histories were unremarkable. 
Family history of neurological diseases was not stated. He presented to us at the age of 3 
years with walking difficulty and was noticed to have tight hip adductors, hamstrings and 
tendo achilles. He was initially diagnosed with spastic diplegic cerebral palsy. Magnetic 
resonance imaging (MRI) of his brain and thoraco-lumbo-sacral spine revealed no pathology. 
Nerve conduction studies showed normal sensory and motor conduction velocities. The 
spasticity in his lower limbs increased and was accompanied by brisk reflexes, bilateral 
ankle clonus and Babinski signs despite physiotherapy and orthotic treatment. His upper 
limb functions were normal, as was his bulbar system. He had no cerebellar ataxia, and had 
normal bladder and bowel control, normal intelligence and language function, and normal 
vibration sensation. At the age of 6 years, he was diagnosed as having early-onset pure 
spastic paraplegia. He could walk indoors and outdoors and climb stairs holding onto a 
railing. His functional mobility was classified as gross motor function classification system 
(GMFCS) level 2. On further investigation of the family history, it was found that the father, 
aged 40 years (II-2) and elder sister, aged 9 years (III-1) had similar symptoms with onsets 
at age 3 to 4 years (Fig a). Both of them showed neurological abnormalities similar to those 
of the proband and were being managed at another regional hospital. They could walk 
with spastic gaits, with no significant functional limitations, and did not require supportive 
devices. The elder sister was a community walker capable of going up and down stairs with 
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Hereditary spastic paraplegias are a heterogeneous group of chronic central motor system 
disorders, characterised by progressive lower limb spasticity. Hereditary spastic paraplegia 
is clinically classified into pure and complicated forms, by the absence or presence of 
additional neurological or extra-neurological features. Hereditary spastic paraplegias follow 
all modes of inheritance and the pure-form autosomal dominant type is the one most 
commonly reported. Spastic paraplegia 4, autosomal dominant (SPG4, MIM#182601) and 
spastic paraplegia 3, autosomal dominant (SPG3A, MIM#182600), account for most autosomal 
dominant hereditary spastic paraplegias. Using DNA mutation analysis, the authors identified 
an SPG3A missense mutation (p.R239C) in a Chinese family where three members have early-
onset pure spastic paraplegia. To our knowledge, this is the first report of a gene mutation 
in hereditary spastic paraplegias in our locality. DNA-based diagnosis plays a key role in the 















no limitations. Her functional mobility was classified 
as GMFCS level 1. There had been no regression in her 
motor ability to date. The father had tendon release 
surgery during childhood and, aside from low back 
pain, did not have significant orthopaedic problems 
or joint contractures. A mild regression in his motor 
ability had been noticed since early adulthood. He 
could no longer walk up and down stairs without 
assistance.
 Mutation analysis of the SPG3A gene was 
performed. Peripheral blood samples were collected 
from the index patient (III-2), his father (II-2), and 
his elder sister (III-1) after informed consent had 
been obtained. Genomic DNA was extracted using 
a QIAamp Blood Kit (Qiagen, Hilden, Germany). The 
coding exons and the flanking introns of the SPG3A 
gene were amplified using polymerase chain reaction 
(PCR). Primer sequences are available upon request. 
Amplification was performed using the touch-down 
method: 94ºC for 12 min, 10 cycles of 94ºC for 30 s, 
59ºC for 30 s (the temperature was lowered 1ºC for 
each cycle), 72ºC for 30 s; 30 cycles of 94ºC for 45 s, 
53ºC for 30s, 72ºC for 30 s and a final extension at 
72ºC for 8 min. The reaction mixture (final volume 
20 mL) contained 10X PCR buffer (Qiagen, Hilden, 
Germany), 5X Q-solution (Qiagen, Hilden, Germany), 
2 mM magnesium chloride, 200 µM dNTP, 1 µM of 
each primer, 0.625 units HotStarTaq polymerase 
and 50 ng DNA template. The PCR products were 
sequenced directly using the BigDye Terminator 
cycle sequencing kit (Applied Biosystems, Foster City, 
CA, US).
 A known disease-causing mutation of SPG3A, 
arginine-to-cysteine substitution at codon 239 
(p.R239C),2 was identified in the proband (III-2), his 
father (II-2), and his elder sister (III-1) [Fig b].
Discussion
Hereditary spastic paraplegia is a group of 
neurodegenerative disorders characterised by 
progressive spasticity of the lower limbs caused by 
pyramidal tract dysfunction. It is classified clinically 
according to the family history, mode of inheritance, 
age of onset, and the extent and features of the 
neurological involvement, into pure and complicated 
types. In the pure type, spasticity is limited to the 
lower limbs. In the complicated type, spasticity is 
associated with other neurological signs, including 
ataxia, mental retardation, extrapyramidal signs, 
visual dysfunction, or epilepsy. With the recent 
discovery of multiple genes and loci involved in 
HSP, the clinical variability is further complicated by 
the extended genetic heterogeneity. Therefore, the 
clinicians need to make a meticulous enquiry into 
the age of onset and clinical and family history, elicit 
well-defined neurological patterns of involvement, 
and perform cerebral and spinal MRI to detect 
associated abnormalities such as cerebellar or corpus 
callosum atrophy or to exclude leukodystrophy, to 
guide prioritisation of molecular testing. Depienne 
et al6 have proposed a work-up for molecular studies 
for different types of HSP (Table).
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FIG.  (a) Pedigree of the reported family with spastic paraplegia 3, autosomal 
dominant (SPG3A). (b) The DNA sequences (in sense direction) of III-2 (left), II-2 
(middle), and III-1 (right) show p.R239C (arrows)
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 Mutations in the SPG4 gene (spastin protein) are 
responsible for about 40% of cases of ADHSP, while 
SPG3A accounts for about 10% of cases.7 In early-
onset ADHSP, the SPG3A gene mutation is the most 
common.1 Other forms, such as SPG6, SPG8, SPG10, 
SPG12, SPG13, SPG19, SPG31, SPG33, and SPG37, 
have also been reported to be associated with the 
uncomplicated form of ADHSP.6,7 The identification of 
a known mutation in the SPG3A gene in the proband 
and other family members is important for providing 
a prognosis and guiding genetic counselling. Dürr 
et al8 studied the clinical features of 34 HSP patients 
with SPG3A mutation and found that: the mean age 
of symptom onset was 4.6±3.9 years; none had upper 
limb spasticity; 13% had decreased vibration sense 
in the ankles; 25% had bladder disturbances; and 
none had cerebellar and bulbar signs. After a mean 
duration of 32 years, less than 25% of these patients 
required a walking aid or a wheelchair. Dürr et al8 
also compared the clinical characteristics of SPG3A 
with those of SPG4 and non-SPG3A phenotypes, and 
it was found that SPG3A patients had an earlier age 
of symptom onset, pyramidal signs restricted to the 
lower limbs, fewer sphincter disturbances, and less 
reduction in vibration sensation.
 More than 30 different mutations in the 
SPG3A gene have been reported and the genotype-
phenotype correlation has been widely studied but 
is not well established.4,6 The missense mutation, 
p.R239C, detected in our cases, is a known mutation 
which has been identified in other ethnic groups.2,5,9,10 
Li et al11 found one novel mutation (p.H189D) and 
p.R239C mutation in two families when screening for 
SPG3A mutation in 20 families and 23 sporadic cases 
in the Han Chinese population.
 Children with early-onset and non-progressive 
spasticity of the lower limbs are commonly diagnosed 
with spastic diplegic cerebral palsy. One must be 
cautious when making this diagnosis, particularly in 
cases with no apparent underlying causes, minimal 
hand dysfunction, and normal intelligence. It is 
important to investigate the family history in detail 
and search for consanguineous marriage if HSP is 
suspected. In our case, family history of neurological 
disorders was not stated initially. Information about 
the other family members was given when all 
investigations proved negative and when consent 
for genetic testing was requested. It has also been 
reported that the diagnosis of ADHSP is sometimes 
difficult to make because a family history is often 
absent. A negative family history may be caused 
by a number of factors. The age of symptom onset 
may vary within the same family, hence individuals 
with affected children may not have developed 
symptoms at the time of evaluation. Mildly affected 
family members may not report any problems 
despite the presence of definite spasticity. Causative 
genes can have incomplete penetrance, masking 
the vertical transmission of mutation.12 Hereditary 
spastic paraplegia should also be considered in cases 
of idiopathic infantile- or childhood-onset spastic 
paraplegia with a negative family history as de-novo 
mutations in causative genes are not uncommon.12,13
 In summary, we describe a family with childhood 
onset of HSP due to mutation in the SPG3A gene. To 
the best of our knowledge, this is the first such family 
to have genetic confirmation of this disorder in our 
locality. DNA-based evaluation plays a key role in the 
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Pure > complicated SPG4 SPG4 SPG4





Thin corpus callosum SPG11 SPG11
Cerebellar atrophy SPG7
Ataxia ARSACS
TABLE. Prioritising molecular testing in hereditary spastic paraplegia (HSP)6
* MRI denotes magnetic resonance imaging
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